View Older Stories View More Recent Stories
-
Leerink Partners on Rhythm Pharmaceuticals (RYTM): CHMP's positive opinion, language shows potential for broad EU labeling
-
TD Cowen: 'Rhythm Pharmaceuticals (RYTM) is a top smid biotech pick'
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $105 at H.C. Wainwright
-
PANTHERx selected as exclusive U.S. pharmacy for IMCIVREE expansion
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $100 at H.C. Wainwright
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $130 at RBC Capital
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $130 at Needham
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $152 at Citizens on 'Disappointing' Phase 3 EMANATE Trial
-
Stifel says Buy rated on Rhythm Pharmaceuticals (RYTM) despite EMANATE failure
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo
-
Jefferies Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM): "We like RYTM into the next 6 months"
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $140 at Canaccord
-
Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens After Trial Data
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Guggenheim
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $176 at Citizens on Imcivree Growth Potential
-
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 9c
-
RBC Capital Starts Rhythm Pharmaceuticals (RYTM) at Outperform; 'Set' Up to Hit High Notes in Rare Obesity'
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $125 at H.C. Wainwright
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $130 at TD Cowen
-
Rhythm Pharmaceuticals reports $57M Q4 revenue, 50% annual growth
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $123 at H.C. Wainwright
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $140 at Guggenheim
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $141 at Canaccord Genuity
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $167 at Citizens
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $157 at Goldman Sachs
-
TD Cowen Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $150 at Morgan Stanley
-
Raymond James on Aardvark (AARD): 'we think ARD-101’s value proposition as potentially best-in-class
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $145 at Needham
-
Citi Starts Rhythm Pharmaceuticals (RYTM) at Buy, PT $136
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $141 at Goldman Sachs
-
Rhythm Pharmaceuticals faces FDA review delay for obesity drug
-
Rhythm gets public reimbursement for IMCIVREE in five Canadian provinces
-
Oppenheimer Downgrades Rhythm Pharmaceuticals (RYTM) to Perform
-
Rhythm Pharmaceuticals (RYTM) Misses Q3 EPS by 11c, provides guidance
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $110 at H.C. Wainwright
-
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $157 at Goldman Sachs
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $122 at Morgan Stanley
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
-
FDA accepts Rhythm Pharmaceuticals' setmelanotide filing for rare obesity
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $100 at H.C. Wainwright
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $135 at Citizens JMP
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $110 at TD Cowen
-
Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 8c

